Targeting Sphingosine-1-Phosphate Signaling Attenuates Doxorubicin-Aggravated Bone Loss in Obese Breast Cancer Mice

Abstract

Although chemotherapy-induced bone loss is well-recognized during breast cancer treatment, the underlying mechanism remains to be further elucidated, especially in patients with obesity. In this study, the objective was to investigate the impact of genomic silencing and pharmacological inhibition of S1P synthesis on bone loss in doxorubicin-induced obese breast cancer mice. In vitro study, upon the treatment of doxorubicin combined with palmitic acid, the S1P generated by 4T1 cells was significantly increased, resulting in an increase in osteoclastogenesis by activating the S1PR1/p-STAT3/NFATc-1 pathway in bone marrow-derived macrophages. In vivo study, pharmacological intervention with Sphingosine kinases (SPHK) antagonist SKI II or biological inhibition with SPHK1 and SPHK2 short hairpin RNA significantly reduced S1P production and rescued the obese breast cancer-bearing mice from doxorubicin-induced bone loss, manifested by the decreased osteoclastogenesis and recovered bone microarchitecture. Similarly, the administration of the S1PR1 antagonist FTY720 also alleviated bone loss in the breast cancer-bearing mice fed a high-fat diet. These studies indicate that genetic silencing and pharmacological inhibition can suppress S1P-dependent bone loss in doxorubicin-induced obese breast cancer mice. S1P shows promise as a potential drug target for preventing chemotherapy-induced bone loss in patients.

Keywords

bone loss / breast cancer / doxorubicin / obesity / sphingosine-1-phosphate

References

[1] S. Loibl, P. Poortmans, M. Morrow, C. Denkert, and G. Curigliano, “Breast Cancer,” Lancet 397 (2021): 1750.

[2] A. Lipton, R. Uzzo, R. J. Amato, et al., “The Science and Practice of Bone Health in Oncology: Managing Bone Loss and Metastasis in Patients With Solid Tumors,” Journal of the National Comprehensive Cancer Network 7, no. S7 (2009): S1.

[3] S. Choi, M. A. Whitman, A. A. Shimpi, et al., “Bone-Matrix Mineralization Dampens Integrin-Mediated Mechanosignalling and Metastatic Progression in Breast Cancer,” Nature Biomedical Engineering 7 (2023): 1455.

[4] N. J. Engmann, M. K. Golmakani, D. L. Miglioretti, B. L. Sprague, and K. Kerlikowske, “Population-Attributable Risk Proportion of Clinical Risk Factors for Breast Cancer,” JAMA Oncology 3 (2017): 1228.

[5] A. Aminian, R. Wilson, A. Al-Kurd, et al., “Association of Bariatric Surgery With Cancer Risk and Mortality in Adults With Obesity,” JAMA 327 (2022): 2423.

[6] D. S. M. Chan, A. R. Vieira, D. Aune, et al., “Body Mass Index and Survival in Women With Breast Cancer-Systematic Literature Review and Meta-Analysis of 82 Follow-Up Studies,” Annals of Oncology 25 (2014): 1901.

[7] H. Q. Duong and M. Maugham-Macan, “Fracture Risk in Breast Cancer: Does Obesity Have an Effect? A Scoping Review,” Journal of Bone Oncology 36 (2022): 100449.

[8] U. Langeh, V. Kumar, P. Ahuja, C. Singh, and A. Singh, “An Update on Breast Cancer Chemotherapy-Associated Toxicity and Their Management Approaches,” Health Sciences Review 9 (2023): 100119.

[9] C. T. Axelsen, A. B. Jensen, E. H. Jakobsen, and T. Bechmann, “Bone Loss During Neoadjuvant/Adjuvant Chemotherapy for Early Stage Breast Cancer: A Retrospective Cohort Study,” Molecular and Clinical Oncology 8 (2018): 767.

[10] T. Saarto, C. Blomqvist, M. Välimäki, P. Mäkelä, S. Sarna, and I. Elomaa, “Chemical Castration Induced by Adjuvant Cyclophosphamide, Methotrexate, and Fluorouracil Chemotherapy Causes Rapid Bone Loss That Is Reduced by Clodronate: A Randomized Study in Premenopausal Breast Cancer Patients,” Journal of Clinical Oncology 15 (1997): 1341.

[11] Y. A. Hannun and L. M. Obeid, “Sphingolipids and Their Metabolism in Physiology and Disease,” Nature Reviews Molecular Cell Biology 19 (2018): 175.

[12] N. J. Pyne and S. Pyne, “Sphingosine 1-Phosphate and Cancer,” Nature Reviews Cancer 10 (2010): 489.

[13] J. M. Grewe, P. R. Knapstein, A. Donat, et al., “The Role of Sphingosine-1-Phosphate in Bone Remodeling and Osteoporosis,” Bone Research 10 (2022): 34.

[14] S. Weske, M. Vaidya, A. Reese, et al., “Targeting Sphingosine-1-Phosphate Lyase as an Anabolic Therapy for Bone Loss,” Nature Medicine 24 (2018): 667.

[15] B. Ogretmen, “Sphingolipid Metabolism in Cancer Signalling and Therapy,” Nature Reviews Cancer 18 (2018): 33.

[16] X. Zheng, W. Li, L. Ren, et al., “The Sphingosine Kinase-1/Sphingosine-1-Phosphate Axis in Cancer: Potential Target for Anticancer Therapy,” Pharmacology & Therapeutics 195 (2019): 85.

[17] N. Rostami, A. Nikkhoo, A. Ajjoolabady, et al., “S1PR1 as a Novel Promising Therapeutic Target in Cancer Therapy,” Molecular Diagnosis & Therapy 23 (2019): 467.

[18] M. Nagahashi, A. Yamada, E. Katsuta, et al., “Targeting the SphK1/S1P/S1PR1 Axis That Links Obesity, Chronic Inflammation, and Breast Cancer Metastasis,” Cancer Research 78 (2018): 1713.

[19] H. Wang, T. Li, Y. Jiang, et al., “Force-Loaded Cementocytes Regulate Osteoclastogenesis via S1P/S1PR1/Rac1 Axis,” Journal of Dental Research 102 (2023): 1376.

[20] G. T. Kunkel, M. Maceyka, S. Milstien, and S. Spiegel, “Targeting the Sphingosine-1-Phosphate Axis in Cancer, Inflammation and Beyond,” Nature Reviews Drug Discovery 12 (2013): 688.

[21] L. Kappos, J. Antel, G. Comi, et al., “Oral Fingolimod (FTY720) for Relapsing Multiple Sclerosis,” New England Journal of Medicine 355 (2006): 1124.

[22] S. Zhao, M. G. Adebiyi, Y. Zhang, et al., “Sphingosine-1-Phosphate Receptor 1 Mediates Elevated IL-6 Signaling to Promote Chronic Inflammation and Multitissue Damage in Sickle Cell Disease,” FASEB Journal 32 (2018): 2855.

[23] W. J. Valentine, G. N. Kiss, J. Liu, et al., “(S)-FTY720-Vinylphosphonate, An Analogue of the Immunosuppressive Agent FTY720, Is a Pan-Antagonist of Sphingosine 1-Phosphate GPCR Signaling and Inhibits Autotaxin Activity,” Cellular Signalling 22 (2010): 1543.

[24] T. Rana, A. Chakrabarti, M. Freeman, and S. Biswas, “Doxorubicin-Mediated Bone Loss in Breast Cancer Bone Metastases Is Driven by an Interplay Between Oxidative Stress and Induction of TGFβ,” PLoS One 8 (2013): e78043.

[25] M. Kciuk, A. Gielecińska, S. Mujwar, et al., “Doxorubicin—An Agent With Multiple Mechanisms of Anticancer Activity,” Cells 12 (2023): 659.

[26] J. Bonica, C. Clarke, L. M. Obeid, C. Luberto, and Y. A. Hannun, “Upregulation of Sphingosine Kinase 1 in Response to Doxorubicin Generates an Angiogenic Response via Stabilization of Snail,” FASEB Journal 37 (2023): e22787.

[27] R. Xu, M. Garcia-Barros, S. Wen, et al., “Tumor Suppressor p53 Links Ceramide Metabolism to DNA Damage Response Through Alkaline Ceramidase 2,” Cell Death & Differentiation 25 (2018): 841.

[28] M. Nagahashi, S. Ramachandran, E. Y. Kim, et al., “Sphingosine-1-Phosphate Produced by Sphingosine Kinase 1 Promotes Breast Cancer Progression by Stimulating Angiogenesis and Lymphangiogenesis,” Cancer Research 72 (2012): 726.

[29] K. Takabe and S. Spiegel, “Export of Sphingosine-1-Phosphate and Cancer Progression,” Journal of Lipid Research 55 (2014): 1839.

[30] M. Nagahashi, K. Yuza, Y. Hirose, et al., “The Roles of Bile Acids and Sphingosine-1-Phosphate Signaling in the Hepatobiliary Diseases,” Journal of Lipid Research 57 (2016): 1636.

[31] S. Chakrabarty, Q. Bui, L. Badeanlou, et al., “S1P/S1PR3 Signalling Axis Protects Against Obesity-Induced Metabolic Dysfunction,” Adipocyte 11 (2022): 69.

[32] G. M. Kowalski, A. L. Carey, A. Selathurai, B. A. Kingwell, and C. R. Bruce, “Plasma Sphingosine-1-Phosphate Is Elevated in Obesity,” PLoS One 8 (2013): e72449.

[33] S. Ito, S. Iwaki, K. Koike, et al., “Increased Plasma Sphingosine-1-Phosphate in Obese Individuals and Its Capacity to Increase the Expression of Plasminogen Activator Inhibitor-1 in Adipocytes,” Coronary Artery Disease 24 (2013): 642.

[34] E. Katsuta, L. Yan, M. Nagahashi, et al., “Doxorubicin Effect Is Enhanced by Sphingosine-1-Phosphate Signaling Antagonist in Breast Cancer,” Journal of Surgical Research 219 (2017): 202.

[35] X. Z. Liu, A. Rulina, M. H. Choi, et al., “C/EBPB-Dependent Adaptation to Palmitic Acid Promotes Tumor Formation in Hormone Receptor Negative Breast Cancer,” Nature Communications 13 (2022): 69.

[36] J. Ryu, H. J. Kim, E. J. Chang, H. Huang, Y. Banno, and H. H. Kim, “Sphingosine 1-phosphate as a Regulator of Osteoclast Differentiation and osteoclast-osteoblast Coupling,” EMBO Journal 25 (2006): 5840.

[37] L. Pederson, M. Ruan, J. J. Westendorf, S. Khosla, and M. J. Oursler, “Regulation of Bone Formation by Osteoclasts Involves Wnt/BMP Signaling and the Chemokine sphingosine-1-phosphate,” Proceedings of the National Academy of Sciences 105 (2008): 20764.

[38] Q. Wu, X. Zhou, D. Huang, Y. Ji, and F. Kang, “IL-6 Enhances Osteocyte-Mediated Osteoclastogenesis by Promoting JAK2 and RANKL Activity In Vitro,” Cellular Physiology and Biochemistry 41 (2017): 1360.

[39] D. S. Amarasekara, H. Yun, S. Kim, N. Lee, H. Kim, and J. Rho, “Regulation of Osteoclast Differentiation by Cytokine Networks,” Immune Network 18 (2018): e8.

[40] Z. Jie, S. Wang, Q. Ma, et al., “Pexmetinib Suppresses Osteoclast Formation and Breast Cancer Induced Osteolysis via P38/STAT3 Signal Pathway,” Journal of Bone Oncology 35 (2022): 100439.

[41] M. Ishii, J. Kikuta, Y. Shimazu, M. Meier-Schellersheim, and R. N. Germain, “Chemorepulsion by Blood S1P Regulates Osteoclast Precursor Mobilization and Bone Remodeling in Vivo,” Journal of Experimental Medicine 207 (2010): 2793.

[42] M. H. Graler and E. J. Goetzl, “The Immunosuppressant FTY720 Down-Regulates Sphingosine 1-Phosphate G-Protein-Coupled Receptors,” FASEB Journal 18 (2004): 551.

[43] K. J. French, R. S. Schrecengost, B. D. Lee, et al., “Discovery and Evaluation of Inhibitors of Human Sphingosine Kinase,” Cancer Research 63 (2003): 5962.

[44] M. Ishii, J. G. Egen, F. Klauschen, et al., “Sphingosine-1-phosphate Mobilizes Osteoclast Precursors and Regulates Bone Homeostasis,” Nature 458 (2009): 524.

[45] H. Han, J. Chen, J. Li, et al., “Enhancing Apoptosome Assembly via Mito-Biomimetic Lipid Nanocarrier for Cancer Therapy,” Advanced Functional Materials 33 (2023): 2305316.

[46] M. Chen, Y. Zhang, P. Zhou, et al., “Substrate Stiffness Modulates Bone Marrow-Derived Macrophage Polarization Through NF-κB Signaling Pathway,” Bioactive Materials 5 (2020): 880.

[47] Y. Mao, Y. Chen, Y. Fu, et al., “miR-346-3p Promotes Osteoclastogenesis via Inhibiting TRAF3 Gene,” In Vitro Cellular & Developmental Biology-Animal 56 (2020): 533.

[48] P. Zhuang, Y. Chen, Y. Zhang, et al., “Regulating Macrophage Glucose Metabolism Homeostasis via Mitochondrial Rheostats by Short Fiber-Microsphere Scaffolds for Bone Repair,” Bioactive Materials 49 (2025): 399.

[49] Q. Gu, M. Chen, Y. Zhang, Y. Huang, H. Yang, and Q. Shi, “Haem Oxygenase-1 Induction Prevents Glucocorticoid-Induced Osteoblast Apoptosis Through Activation of Extracellular Signal-Regulated Kinase1/2 Signalling Pathway,” Journal of Orthopaedic Translation 19 (2019): 29.

[50] D. W. Li, F. L. He, J. He, et al., “From 2D to 3D: The Morphology, Proliferation and Differentiation of MC3T3-E1 on Silk Fibroin/Chitosan Matrices,” Carbohydrate Polymers 178 (2017): 69.

[51] J. Niu, Y. Zhang, Z. Jiang, et al., “Stem Cell Fishing at Bone-Implant Interface: A Cell-Clicking Bioadhesion Strategy to Enhance Osteointegration,” Advanced Functional Materials 36 (2026): e14351.

[52] H. Shen, J. He, X. Ling, et al., “Wheel-Running Exercise Protects Ovariectomized Mice From Bone Loss via IFN-γ-Mediated Suppression of the NF-κB and MAPK Pathways,” Oxidative Medicine and Cellular Longevity 2022 (2022): 2030818.

[53] Y. Zhang, W. Yang, W. Xiong, et al., “Disrupting Complement-Inflammation Positive Feedback Circuit via Oligonucleotide Hydrogel Microspheres for Reversing Joint Inflammation,” Advanced Materials 38 (2026): e18378.

[54] Y. Zhou, X. He, W. Zhang, et al., “Cell-Recruited Microspheres for OA Treatment by Dual-Modulating Inflammatory and Chondrocyte Metabolism,” Materials Today Bio 27 (2024): 101127.

[55] J. Wang, Y. Xue, Y. Wang, et al., “BMP-2 Functional Polypeptides Relieve Osteolysis Via Bi-Regulating Bone Formation and Resorption Coupled With Macrophage Polarization,” NPJ Regenerative Medicine 8 (2023): 6.

[56] W. N. Arifin and W. M. Zahiruddin, “Sample Size Calculation in Animal Studies Using Resource Equation Approach,” Malaysian Journal of Medical Sciences 24 (2017): 101.

RIGHTS & PERMISSIONS

2026 The Author(s). Smart Medicine published by Wiley-VCH GmbH on behalf of Wenzhou Institute, University of Chinese Academy of Sciences.